MAP to Provide Access to Ruxolitinib, for Patients With Polycythemia Vera

Sponsor
Novartis Pharmaceuticals
Study ID
NCT05269771
Status
No Longer Available

Conditions

  • Polycythemia Vera

Eligibility Criteria

Sex
ALL
Age
12 Years - 99 Years
Healthy Volunteers
Not accepted

Interventions

  • Ruxolitinib — DRUG
    Patients may self-administer daily ruxolitinib tablets qd or bid orally, without regard to food, in accordance with specified dosing schedule provided by the investigator.

Study Details

The purpose of this Cohort Treatment Plan is to allow access to ruxolitinib for eligible patients diagnosed with Polycythemia Vera. The patient's Treating Physician should follow the suggested treatment guidelines and comply with all local health authority regulations.

Key Dates

Status verified
Oct 2025

Related Studies